Angiotech Pharmaceuticals (ANP.TO) Buy, Sell…

Angiotech Pharmaceuticals (ANP.TO)

0.00

-0.00 (0.00%)

2 watching

TRADE

At the same time there stent was approved, Johnson & Johnson went partners with partners with Guidance. Long-term, this stock and their partner Boston Scientific will be very good.

Wealthica Track your Stocks in your Watch List

BUY

Approval has been given for Boston Scientific to sell its drug-coated stent. A safe way to play the stent market. Also have a relationship with Guidant which expects to put a stent in the market.

BUY

Down today, but things it's a short term blip. Isn't taking it out of its trend. There is a risk that their stent will not be approved but feels it is a small risk.

BUY

Still sees some upside in the long-term. Fundamentals are good.

HOLD

Riding the waves of Boston Scientific. Keep riding it.

BUY

Like. Nice place in market. They earn money. They're one of the best in the fierl. Positive outlook

TRADE

Moving average is rising. Just had a breakout. Best time to jump in is when stock hits all time high.

HOLD

Very expensive. Earnings aren't there yet. They have to sell their products. Stock market price is on potential. The potential is there, so hang on.

Wealthica Track your Stocks in your Watch List

BUY

Have done wonderfully. A stock split is due in February. Demand for their product is very strong. Not cheap. Management has done really well.

WEAK BUY

Has a volatiltiy of earnings, trading higher than it should.

BUY

A world-class company. The drugs that cover the stents has just been approved by the FDA. A great leverage play on Boston Scientific getting a big part of the stent market.

DON'T BUY

A lot of its good news is priced into the stock right now.

BUY

Now crossing into profitability. When their stent hits the US market, the earnings will drive a lot higher.

BUY

Has moved up dramatically during the summer. Still a transforming technology. Can probably stick it in your bottom drawer and in 3/4 years time will have done very nicely.

BUY

They have a deal with Boston Scientific to produce stents. Competition is having problems with their product, which is good news for this stock.

Showing 91 to 105 of 140 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Angiotech Pharmaceuticals (ANP.TO)